Argentina’s Grupo Insud is building a biologics platform: mAbxience exports biosimilars across three continents while Sinergium anchors Latin America’s mRNA vaccine sovereignty.
Argentina’s Grupo Insud is building a biologics platform: mAbxience exports biosimilars across three continents while Sinergium anchors Latin America’s mRNA vaccine sovereignty.
Medtronic’s $650M bid for SPR Therapeutics brings the FDA-cleared SPRINT Peripheral Nerve Stimulation System into its portfolio, offering a 60-day, non-permanent pain therapy backed by 6,100-patient real-world data showing 71% …
ANVISA has approved serplulimab as the only anti-PD-1 authorized in Brazil for extensive-stage small cell lung cancer, giving Abbott a regulatory head start before larger checkpoint inhibitor rivals.
You must be logged in to post a comment.